Wire · opportunities
Phase 3 study shows aQIVc superior to comparators in older adults
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 September 2026 · Fusion42 review
A Phase 3 trial showed CSL Seqirus’s aQIVc vaccine for older adults outperforms existing adjuvanted egg-based and recombinant vaccines in immunogenicity. The vaccine combines cell-based manufacturing, MF59 adjuvant, and higher antigen dose, offering improved immune response durability in adults aged 50 and older.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You can expect faster access and stronger usage mandates for aQIVc in markets adopting the Lancet data. If you supply older adult vaccines, prepare for a shift in procurement favouring cell-based, adjuvanted, higher-dose formulations.
◆ Coverage
1 source · 11 Sep 2026
◆ Related on Wire
◆ Topics